M.D. Anderson, Cleveland Clinic Among Group of Leading Cancer Centers
Presenting Cryoablation Data
IRVINE, Calif., May 21 /PRNewswire-FirstCall/ -- Endocare, Inc. (Nasdaq: ENDO), an innovative medical device company focused on the development of minimally invasive technologies used by urologists and interventional radiologists for tissue and tumor ablation, announced today that cryoablation, a minimally invasive method of freezing cancerous tumors to destroy them, was the focus of 17 clinical studies presented at the six-day annual meeting of the American Urological Association (AUA) in Orlando, which is the largest urology meeting of the year.
Also, a total of six post-graduate educational courses and workshops related to cryoablation were sponsored by the AUA and, for the first time, the AUA adopted a specific set of prostate cancer clinical guidelines for cryoablation. A panel, led by Richard J. Babaian M.D. professor and senior medical director at M.D. Anderson Physician Network, announced a set of best practice statements for primary cryoablation, salvage cryoablation and focal cryoablation.
"The positive outcomes cryoablation has had for thousands of patients
were evident in a variety of clinical studies presented by leading
physicians and researchers throughout this year's AUA annual meeting," said
Endocare Chairman, CEO and President Craig T. Davenport. "The breadth of
attention that the AUA now pays to cryoablation, including educational
courses, workshops and the adoption of AUA-sponsored clinical guidelines,
underscores the acceptance of cryoablation as a safe and effective,
minimally invasive treatment for prostate cancer and kidney cancer."
Highlights from the 17 studies include:
-- A wide-ranging review of the outcomes of cryoablation in 2,558 primary
prostate cancer patients showed efficacy of cryoablation in terms of
biochemical survival and low morbidity. The average age of the
patients, all part of the nationwide Cryo-On-Line Database (COLD)
Registry, was 70 years and 419 of the patients had more than five years
-- A 10-year, retrospective review of 78 patients at the University of
Texas M.D. Anderson Cancer Center demonstrated the effectiveness of
cryoablation for prostate cancer patients whose cancer returned after
being originally treated with radiation. After 10 years, more than 80
percent of the patients were disease free after cryoablation and the
investigators concluded that salvage cryoablation is curative in
approximately one-third of patients at 10-year follow up.
-- The first, multi-center study of focal, or partial gland, cryoablation
for 341 prostate cancer patients demonstrated that more than half of
the patients who were potent before the therapy were again potent after
six months, and more than 74 percent resumed potency within 36 months.
Focal cryoablation is designed to destroy the tumors in the prostate
while sparing the nerves to retain potency. These patients are also
part of the COLD Registry.
-- An 88-patient Cleveland Clinic study of the long term disease-free
survival rates (more than five years) of kidney cancer patients showed
that laparoscopic kidney cryoablation is an effective treatment in
select patients. The investigators determined that cancer-specific
survival of 95 percent is possible at five years and 88 percent is
possible at 10 years.
-- Six AUA-sponsored courses and workshops related to cryoablation
focused on prostate ultrasound, abdominal ultrasound, laparoscopic
techniques, renal ablation, needle ablation of the kidney and
cryoablation of the prostate.
Endocare, Inc. -- http://www.endocare.com -- is an innovative medical device company focused on the development of minimally invasive technologies for tissue and tumor ablation. Endocare has initially concentrated on developing technologies for the treatment of prostate cancer and believes that its proprietary technologies have broad applications across a number of markets, including the ablation of tumors in the kidney, lung and liver and palliative intervention (treatment of pain associated with metastases).
Statements contained in this release that are not historical facts are
forward-looking statements that involve risks and uncertainties. Among the
important factors which could cause actual results to differ materially
from those in the forward-looking statements include, but are not limited
to, those discussed in "Risk Factors" in the Company's Forms 10-K, Forms
10-Q, and other filings with the Securities and Exchange Commission. Such
risk factors include, but are not limited to, uncertainty regarding the
effects of the studies described in this press release and any future
follow up data. The actual results that the Company achieves may differ
materially from any forward-looking statements due to such risks and
uncertainties. The Company undertakes no obligation to revise, or update
publicly, any forward-looking statements for any reason.
Allen & Caron, Inc.
Allen & Caron, Inc.
For Additional Information:
Craig T. Davenport, CEO
Michael R. Rodriguez, CFO
|SOURCE Endocare, Inc.|
Copyright©2008 PR Newswire.
All rights reserved